(Q24305251)

Gene Ontology release 2020-05-02

Gene Ontology ID

GO:1903028

regulation of opsonization

2 references

Gene Ontology release 2020-05-02

Gene Ontology ID

GO:1903027

Complement component 4 binding protein beta

1 reference

Complement component 4 binding protein alpha

1 reference

Complement component 4B (Chido blood group), copy 2

1 reference

Staphylococcus aureus

1 reference

Pamela S Hair

1

0 references

Sara M Wagner

2

0 references

Patricia T Friederich

3

0 references

Richard R Drake

4

0 references

Julius O Nyalwidhe

5

0 references

Kenji M Cunnion

Bordetella pertussis binds to human C4b-binding protein (C4BP) at a site similar to that used by the natural ligand C4b

6

0 references

language of work or name

English

0 references

publication date

April 2012

0 references

published in

Molecular Immunology

0 references

volume

50

0 references

issue

4

0 references

page(s)

253-61

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Etiology of septic arthritis in children: an update for the new millennium

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Serum complement factor I decreases Staphylococcus aureus phagocytosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Binding of the complement inhibitor C4b-binding protein to Lyme disease borreliae

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Disruption of the alternative pathway convertase occurs at the staphylococcal surface via the acquisition of factor H by Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Staphylococcal innate immune evasion.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Contribution of interactions between complement inhibitor C4b-binding protein and pathogens to their ability to establish infection with particular emphasis on Neisseria gonorrhoeae.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Skin and soft tissue infection: microbiology and epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Streptococcal M protein: structural studies of the hypervariable region, free and bound to human C4BP.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

In-gel digestion for mass spectrometric characterization of proteins and proteomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Osteomyelitis of the long bones

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Human C4b-binding protein, structural basis for interaction with streptococcal M protein, a major bacterial virulence factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Human C4-binding protein. II. Role in proteolysis of C4b by C3b-inactivator

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Staphylococcal complement evasion by various convertase-blocking molecules.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Staphylococcus aureus clumping factor A binds to complement regulator factor I and increases factor I cleavage of C3b

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Immunotherapies for Staphylococcus aureus: current challenges and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

The changing face of Staphylococcus aureus: a continuing surgical challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Logarithmic phase Escherichia coli K1 efficiently avoids serum killing by promoting C4bp-mediated C3b and C4b degradation

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Early expression of SCIN and CHIPS drives instant immune evasion by Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Costs of healthcare-associated methicillin-resistant Staphylococcus aureus and its control

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Clumping factor A interaction with complement factor I increases C3b cleavage on the bacterial surface of Staphylococcus aureus and decreases complement-mediated phagocytosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Immune evasion of leptospira species by acquisition of human complement regulator C4BP.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Capsule production and growth phase influence binding of complement to Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Staphylococcus aureus Cap5O has UDP-ManNAc dehydrogenase activity and is essential for capsule expression

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Availability of complement bound to Staphylococcus aureus to interact with membrane complement receptors influences efficiency of phagocytosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Cleavage of complement C3b to iC3b on the surface of Staphylococcus aureus is mediated by serum complement factor I

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

The innate immune modulators staphylococcal complement inhibitor and chemotaxis inhibitory protein of Staphylococcus aureus are located on beta-hemolysin-converting bacteriophages.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Familial furunculosis associated with community-acquired leukocidin-positive methicillin-susceptible Staphylococcus aureus ST152.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Human complement regulators C4b-binding protein and C1 esterase inhibitor interact with a novel outer surface protein of Borrelia recurrentis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Yersinia enterocolitica serum resistance proteins YadA and ail bind the complement regulator C4b-binding protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Clinical isolates of Streptococcus pneumoniae bind the complement inhibitor C4b-binding protein in a PspC allele-dependent fashion

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

The emerging pathogen Moraxella catarrhalis interacts with complement inhibitor C4b binding protein through ubiquitous surface proteins A1 and A2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Binding of the complement inhibitor C4bp to serogroup B Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Interaction with C4b-binding protein contributes to nontypeable Haemophilus influenzae serum resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021

Binding of complement inhibitor C4b-binding protein contributes to serum resistance of Porphyromonas gingivalis

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLIMM.2012.01.010

7 January 2021